ZYDUSLIFE Zydus Lifesciences Ltd Product Launches Announcement 2025 - FDA Approval On March 16, 2025, Zydus Lifesciences received final approval from the USFDA to manufacture Eluxadoline Tablets, 75 mg and 100 mg, which are used to treat irritable bowel syndrome with diarrhoea, with an annual market value of USD 243.7 million in the US..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Zydus Lifesciences Ltd